Valneva SE (VALN) recently announced that the European Commission (EC) has given it the marketing authorization for Valneva’s single-dose Chikungunya vaccine, IXCHIQ, in Europe. This approval followed the FDA's nod for IXCHIQ in November 2023.The approval was unanimously endorsed by Member States, followed by a rigorous assessment by the European Medicines Agency.It positions Valneva to protect the lives of European populations against Chikungunya outbreaks and make a significant impact on the Chikungunya v ...